In 2017, FDA approved CPX-351 (VYXEOS®, Jazz Pharmaceuticals), a liposomal encapsulation of cytarabine and daunorubicin, with a molar ratio of 5:1 for patients with t-AML or with AML and “myelodysplasia related changes” (AML-MRC). This evidence concerns the gene CD200 and acute myeloid leukemia.